Edinburgh‑based Trogenix closed a $95 million Series A to advance its Odysseus platform, which deploys synthetic super enhancers via AAV vectors to activate therapeutic payloads selectively in cancer cells. The company described a dual‑mechanism payload combining localized prodrug activation with an immune‑stimulating cytokine to convert immunologically cold, aggressive tumors into responsive lesions. Lead investors included IQ Capital and participation from Eli Lilly and others; Trogenix plans a first‑in‑human trial for its glioblastoma program in Q1 2026 and a follow‑on program for colorectal liver metastases. Management framed the approach as a tumor‑selective “Trojan horse” to increase efficacy while limiting systemic toxicity. Investors called the round a vote of confidence in synthetic regulatory element strategies and targeted AAV delivery, though translational hurdles around tumor tropism and payload safety remain central to clinical readouts.